<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351415</url>
  </required_header>
  <id_info>
    <org_study_id>MO22097</org_study_id>
    <secondary_id>2010-022645-14</secondary_id>
    <nct_id>NCT01351415</nct_id>
  </id_info>
  <brief_title>A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label, randomized, multicenter study will evaluate the efficacy and safety of
      bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants
      with advanced non-squamous NSCLC. Participants will be enrolled at documentation of
      progression of disease (PD) after 4-6 cycles of first-line treatment with bevacizumab plus a
      platinum doublet-containing therapy and a minimum of two cycles of bevacizumab maintenance
      treatment prior to PD. Participants will be randomly assigned to one of two treatment arms to
      receive either bevacizumab plus SOC treatment or SOC treatment alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 25, 2011</start_date>
  <completion_date type="Actual">June 25, 2016</completion_date>
  <primary_completion_date type="Actual">June 25, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
    <description>Overall survival (OS) was defined as the time from the date of randomization at first progression of disease to the date of death, regardless of the cause of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)</measure>
    <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
    <description>PFS was defined as the time from start of treatment to the first event of death or PD. Tumor response was assessed by the IRF according to RECIST v1.1. Disease progression or PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS2 is defined as the time between randomization at PD1 and the date of PD2 or death, whichever occurs first. PFS3 is defined as the time between PD2 and the date of PD3 or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Objective Response According to RECIST v1.1</measure>
    <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
    <description>The objective response is defined as complete response (CR) or partial response (PR) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Disease Control According to RECIST v1.1</measure>
    <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
    <description>The disease control rate is defined as CR or PR or stable disease (SD) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started for target lesions and the persistence of 1 or more non-target lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) According to RECIST v1.1</measure>
    <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
    <description>Duration of response is defined as the time that measurement criteria are met for objective response (CR/PR) (whichever status is recorded first) until the first date of progression or death is documented. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than &lt; 10 mm. PR was defined as greater than or equal to ≥30 % decrease in sum of longest diameter of target lesions in reference to baseline sum longest diameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
    <description>An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) According to RECIST v1.1</measure>
    <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
    <description>The time to progression was defined as the time from baseline until disease progression as determined by the RECIST v1.1. TTP2 is defined as the interval between the day of randomization at PD1 and PD2. TTP3 is defined as the interval between the day of PD2 and PD3. PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Are Alive at Month 6, 12, and 18</measure>
    <time_frame>Month 6, 12, 18</time_frame>
    <description>Percentage of participants who were alive at Month 6, 12 and 18 were reported.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">485</enrollment>
  <condition>Non-Squamous Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Bevacizumab + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive bevacizumab on Day 1 of every 21-days cycle along with standard of care (Erlotinib or Docetaxel or Pemetrexed) as second line treatment, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.</description>
    <arm_group_label>Bevacizumab + Standard of Care</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 60 or 75 milligram per meter square (mg/m^2) on Day 1 every 21 days.</description>
    <arm_group_label>Bevacizumab + Standard of Care</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.</description>
    <arm_group_label>Bevacizumab + Standard of Care</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m^2 IV over 10 minutes on Day 1 every 21 days.</description>
    <arm_group_label>Bevacizumab + Standard of Care</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed non-squamous NSCLC

          -  Documented progression of disease (locally recurrent or metastatic) per investigator
             assessment following first-line treatment with 4-6 cycles of Bevacizumab plus a
             platinum doublet-containing chemotherapy regimen and a minimum of 2 cycles of
             Bevacizumab (monotherapy) maintenance treatment prior to first progression of disease

          -  No treatment interruption of Bevacizumab treatment greater than 2 consecutive cycles
             (42 days) between the start of first-line treatment to start of Cycle 1 of second line
             treatment

          -  Randomization within 4 weeks of progression of disease

          -  At least one unidimensionally measurable lesion meeting RECIST v1.1 criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Participants with adequate hematological, liver, and renal function

          -  Female participants must not be pregnant or breast-feeding. Female participants of
             childbearing potential and fertile male participants must agree to use a highly
             effective contraceptive during the trial and for a period of at least 6 months
             following the last administration of trial drug(s)

        Exclusion Criteria:

          -  Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a
             predominant squamous component

          -  Epidermal growth factor receptor (EGFR)-mutation-positive disease according to local
             laboratory testing

          -  History of hemoptysis greater than or equal to (&gt;/=) grade 2 within 3 months of
             randomization

          -  History or evidence of inherited bleeding diathesis or coagulopathy with a risk of
             bleeding and active gastrointestinal bleeding

          -  Major cardiac disease

          -  Treatment with any other investigational agent within 28 days prior to randomization

          -  Known hypersensitivity to bevacizumab or any of its excipients, or any SOC drugs
             foreseen

          -  Malignancy other than NSCLC within 5 years prior to randomization and evidence of any
             other disease that contraindicates the use of an investigational or SOC drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USA Mitchell Cancer Institute</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palo Verde Hema/Onc</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clopton Clinic</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Valley Hematology ; Oncology Medical Group</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <zip>91505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research &amp; Excellence, Inc.</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic; Hematology &amp; Oncology</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-1027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Integrative Cancer Care</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research Institute</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital of Central CT</name>
      <address>
        <city>New Britain</city>
        <state>Connecticut</state>
        <zip>06050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Ct Hema/Onco Assoc; Dept of Oncology</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Cancer Institute - West</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist - MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of Brevard</name>
      <address>
        <city>Rockledge</city>
        <state>Florida</state>
        <zip>32955</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univ Winship Cancer Inst</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summit Cancer Care PC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kootenai Cancer Center</name>
      <address>
        <city>Post Falls</city>
        <state>Idaho</state>
        <zip>83854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexian Brothers Neurosci Inst</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology-Evanston Nthwest Healthcare Kellogg Cancer Care Ctr</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology Hematology Associates, Ltd.</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care &amp; Hematology; Specialists of Chicagoland</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>W. Suburban Ctr for Cncer Care</name>
      <address>
        <city>River Forest</city>
        <state>Illinois</state>
        <zip>60305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of Southwest Indiana</name>
      <address>
        <city>Newburgh</city>
        <state>Indiana</state>
        <zip>47630</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214-3728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Cancer Care</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40245</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Clinic, LLP</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana Oncology Associates</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Cancer Specialists</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Hospital</name>
      <address>
        <city>York</city>
        <state>Maine</state>
        <zip>03909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Health System Research Instit-Annapolis Oncology Ctr</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center; Neely Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann Arbor Hematology Oncology</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital; Hematology Oncology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer &amp; Hematology Center of West Michigan</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro-Minnesota CCOP</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph Oncology</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland CCOP/Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook Univ Cancer Ctr; Medical Oncology Clinic</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794-9447</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Oncology Specialists, PA - Hickory</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Ohio Onc Hematology Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dayton Clinical Oncology Prog</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical; Research Center, LLC</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Hospital; CCOP Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Hospital</name>
      <address>
        <city>Coos Bay</city>
        <state>Oregon</state>
        <zip>97420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lukes Hospital and Health Network</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology &amp; Oncology Assoc; North Eastern Pennsylvania</name>
      <address>
        <city>Dunmore</city>
        <state>Pennsylvania</state>
        <zip>18512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary Medical Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania; Radiation Oncology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of Rhode Island</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center Cancer Institute</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unv of TX SW Med Cntr; Hematology/Onc</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Hematology/ Oncology Associates</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Cancer Care - Roanoke</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Valley Hema and Onc SC</name>
      <address>
        <city>Appleton</city>
        <state>Wisconsin</state>
        <zip>54915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNI OF WISCONSIN SCHOOL OF MEDICINE; GI Oncology Research Group, Paul P Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. Alexander Fleming; Oncology Dept</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1426ANZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Infinito; Oncologia</name>
      <address>
        <city>La Pampa</city>
        <zip>6300</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado de Comunidad; Oncology</name>
      <address>
        <city>Mar Del Plata</city>
        <zip>7600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Parque de Rosario</name>
      <address>
        <city>Rosario</city>
        <zip>S2000DSV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ISIS Clinica Especializada</name>
      <address>
        <city>Santa Fe</city>
        <zip>03000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Viedma</name>
      <address>
        <city>Viedma, Rio Negro</city>
        <zip>8500</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH Hohenems; Abteilung für Pulmologie</name>
      <address>
        <city>Hohenems</city>
        <zip>6845</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie &amp; Onkologie</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lkh Natters; Abt. Für Atemwegs- &amp; Lungenkrankheiten</name>
      <address>
        <city>Natters</city>
        <zip>6161</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.Ö. LKH; Abt. für Lungenkrankheiten</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen; Lungenabt.</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Der Stadt Wien Lainz; V. Medizinische Abt.</name>
      <address>
        <city>Wien</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMZ - Baumgartner Hohe, Pavilion Leopold; 1.Interne Lungenabteilung, Onkologische Tagesklinik</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clin. Europe (Ste Elisabeth)</name>
      <address>
        <city>Bruxelles</city>
        <zip>1180</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleo de Oncologia da Bahia - NOB</name>
      <address>
        <city>Salvador, Bahia</city>
        <state>BA</state>
        <zip>40170-380</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica- Instituto do Câncer do Ceará- ICC</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60125-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedade beneficente de senhoras Hospital Sirio Libanes</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70200-730</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudos e Pesquisas Oncologicas - CESPO</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70390-150</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Câncer de Brasília</name>
      <address>
        <city>Taguatinga</city>
        <state>DF</state>
        <zip>72110-980</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinicas Oncologicas Integradas - COI</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22793-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Caridade de Ijui; Oncologia</name>
      <address>
        <city>Ijui</city>
        <state>RS</state>
        <zip>98700-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Neoplasias Litoral</name>
      <address>
        <city>Itajai</city>
        <state>SC</state>
        <zip>88301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital A. C. Camargo; Oncologia</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>01509-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Jose</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>CEP 01321-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital, Hillerød, Onkologisk Afdeling</name>
      <address>
        <city>Hillerod</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poly Parc Rambot La Provencale; Chimiotherapie Ambulatoire</name>
      <address>
        <city>Aix En Provence</city>
        <zip>13617</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse; Oncologie</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal; Service de Pneumologie</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Nord Ouest;Unite 2c</name>
      <address>
        <city>Gleize</city>
        <zip>69400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Calmette; Pneumologie</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis Pradel; Cardiologie B</name>
      <address>
        <city>Lyon</city>
        <zip>69394</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph; Oncologie Medicale</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Nord; Service d'Oncologie Multidisciplinaire et Innovation Thérapeutique</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ch Lyon Sud; Chir Onc Gyne Sct Jules Courmont</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Rene Dubos; Oncologie</name>
      <address>
        <city>Pontoise</city>
        <zip>95300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ico Rene Gauducheau; Oncologie</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Loire</name>
      <address>
        <city>St-Priest-En-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss; Oncologie Medicale</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hia Sainte Anne; Pneumologie</name>
      <address>
        <city>Toulon</city>
        <zip>83041</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Musse; Pneumologie</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur; Pneumologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi De La Haute Saone De Vesoul; Pneumologie</name>
      <address>
        <city>Vesoul</city>
        <zip>70014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka GmbH; Pneumologie</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. David Borquez</name>
      <address>
        <city>Bergisch Gladbach</city>
        <zip>51465</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen; Klinik für Kardiologie, Angiologie und Pneumologie</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest; Klinik f. Onkologie und Hämatologie</name>
      <address>
        <city>Frankfurt</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LungenClinic Großhansdorf</name>
      <address>
        <city>Großhansdorf</city>
        <zip>22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin I</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum des Saarlandes; Innere Medizin V</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachklinik für Lungenerkrankungen</name>
      <address>
        <city>Immenhausen</city>
        <zip>34376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius Kliniken Karlsruhe; Abteilung Hämatologie / Onkologie</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Koch-Klinik; Pneumologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Christian Geßner</name>
      <address>
        <city>Leipzig</city>
        <zip>04357</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes-Wesling-Klinikum Minden; Onkologische Ambulanz / Tagesklinik</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians Uni Klinik Innenstadt; Medizinische Klinik</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pius-Hospital; Klinik fuer Haematologie und Onkologie</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotiria Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital; 2Nd Oncology Clinic</name>
      <address>
        <city>Piraeus</city>
        <zip>185 47</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Thessaloniki Papanikolaou; Uni Pneumonology Dept.</name>
      <address>
        <city>Thessaloniki</city>
        <zip>570 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diavalkaniko Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Citta Ospedaliera; Divisione Oncologia Medica</name>
      <address>
        <city>Avellino</city>
        <state>Campania</state>
        <zip>83100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico; Uoc Oncologia Medica</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. Di Busto P.O. Di Saronno; U.O. Di Oncologia Medica</name>
      <address>
        <city>Saronno</city>
        <state>Lombardia</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Pisana-Ospedale Cisanello; Dipartimento Cardio Toracico-Pneumologia Ii</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital; Respiratory Medicine</name>
      <address>
        <city>Aichi</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East; Thoracic Oncology</name>
      <address>
        <city>Chiba</city>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center; Thoracic Oncology</name>
      <address>
        <city>Ehime</city>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center, Thoracic Oncology</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center; Thoracic Oncology</name>
      <address>
        <city>Hyogo</city>
        <zip>673-8553</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cardiovascular and Respiratory Center; Respiratory Medicine</name>
      <address>
        <city>Kanagawa</city>
        <zip>236-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Municipal Citizen'S Hospital; Respiratory</name>
      <address>
        <city>Kanagawa</city>
        <zip>240-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miyagi Cancer Center; Respiratory Medicine</name>
      <address>
        <city>Miyagi</city>
        <zip>981-1293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital; Respiratory and Allergy Medicine</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OSAKA CITY GENERAL HOSPITAL;Medical Oncology</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka International Cancer Institute; Thoracic Oncology</name>
      <address>
        <city>Osaka</city>
        <zip>541-8567</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center; Thoracic Oncology</name>
      <address>
        <city>Shizuoka</city>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital; Thoracic Medical Oncology</name>
      <address>
        <city>Tokyo</city>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR, Respiratory Medicine</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>American University of Beirut - Medical Center</name>
      <address>
        <city>Beirut</city>
        <zip>11-236</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de France; Oncology</name>
      <address>
        <city>Beirut</city>
        <zip>16830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middle East Inst. of Health; Oncology</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centenario Hospital Miguel Hidalgo</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Central Sur de Alta Especialidad Petróleos Mexicanos</name>
      <address>
        <city>Mexico City</city>
        <zip>14140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Médico Abc the American British Cowdray Medical Center, I.A.P. - Centro de Cáncer</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis; Afdeling Longziekten</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leyenburg Hospital; Pulmonology</name>
      <address>
        <city>Den Haag</city>
        <zip>2504 LN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis; Dept of Lung Diseases</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis St Jansdal; Dept of Lung Diseases</name>
      <address>
        <city>Harderwijk</city>
        <zip>3844 DG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academisch Ziekenhuis Maastricht</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis; Dept of Lung Diseases</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>College of Medicine &amp; Sciences, Sultan Qaboos University Hospital</name>
      <address>
        <city>Muscat</city>
        <zip>P.O Box 35</zip>
        <country>Oman</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fnsp Fdr Banska Bystrica; Dep of Pneumology&amp;Ftizeology</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FNsP Bratislava, Nemocnica Ruzinov</name>
      <address>
        <city>Bratislava</city>
        <zip>826 06</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vychodoslovensky onkologicky ustav</name>
      <address>
        <city>Kosice</city>
        <zip>04001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inst. of Tb &amp; Respiratory Diseases; Dep. of Oncology</name>
      <address>
        <city>Nitra</city>
        <zip>949 88</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces; Servicio de Oncologia</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Univ. de Alicante; Servicio de Oncologia</name>
      <address>
        <city>Alicante</city>
        <zip>3010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico MD Anderson International Espana</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clínico San Carlos; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz; Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset; Servicio de Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet; Servicio Oncologia</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tawam Hospital; Medical Oncology Department</name>
      <address>
        <city>Al Ain</city>
        <zip>15258</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Oman</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Arab Emirates</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Jordan</country>
    <country>Qatar</country>
  </removed_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2011</study_first_submitted>
  <study_first_submitted_qc>May 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2011</study_first_posted>
  <results_first_submitted>June 20, 2017</results_first_submitted>
  <results_first_submitted_qc>August 17, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2017</results_first_posted>
  <last_update_submitted>August 17, 2017</last_update_submitted>
  <last_update_submitted_qc>August 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This phase 3b study was conducted across 16 different countries and enrolled 485 participants. Participants were 18 years or older and had locally recurrent or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC)</recruitment_details>
      <pre_assignment_details>A total of 485 participants were enrolled and randomized into the study. Of these, 475 participants were treated; 243 participants received bevacizumab plus standard of care (SoC) and 232 participants received SoC alone. The study was terminated 60 months after study start, as per protocol, but was not ended prematurely.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bevacizumab + Standard of Care</title>
          <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated Participants</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
                <participants group_id="P2" count="232"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="240"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial termination by the Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="190"/>
                <participants group_id="P2" count="187"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason unknown</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Never Started</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat population includes all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Bevacizumab + Standard of Care</title>
          <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="245"/>
            <count group_id="B2" value="240"/>
            <count group_id="B3" value="485"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.5" spread="9.61" lower_limit="26" upper_limit="84"/>
                    <measurement group_id="B2" value="61.8" spread="9.29" lower_limit="35" upper_limit="82"/>
                    <measurement group_id="B3" value="61.6" spread="9.44" lower_limit="26" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="155"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival (OS) was defined as the time from the date of randomization at first progression of disease to the date of death, regardless of the cause of death.</description>
        <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
        <population>Intent to treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Standard of Care</title>
            <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival (OS) was defined as the time from the date of randomization at first progression of disease to the date of death, regardless of the cause of death.</description>
          <population>Intent to treat population included all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.86" lower_limit="10.22" upper_limit="13.67"/>
                    <measurement group_id="O2" value="10.22" lower_limit="8.61" upper_limit="11.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The stratification factors for Log-Rank test and Hazard Ratio (HR) are the type of planned 2nd-line SoC treatment, the number of cycles of bevacizumab maintenance treatment prior to first PD and smoking status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1044</p_value>
            <method>Stratified Log-Rank test</method>
            <param_type>Stratified Hazard Ratio</param_type>
            <param_value>0.84</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)</title>
        <description>PFS was defined as the time from start of treatment to the first event of death or PD. Tumor response was assessed by the IRF according to RECIST v1.1. Disease progression or PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS2 is defined as the time between randomization at PD1 and the date of PD2 or death, whichever occurs first. PFS3 is defined as the time between PD2 and the date of PD3 or death, whichever occurs first.</description>
        <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
        <population>Intent to treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Standard of Care</title>
            <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)</title>
          <description>PFS was defined as the time from start of treatment to the first event of death or PD. Tumor response was assessed by the IRF according to RECIST v1.1. Disease progression or PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PFS2 is defined as the time between randomization at PD1 and the date of PD2 or death, whichever occurs first. PFS3 is defined as the time between PD2 and the date of PD3 or death, whichever occurs first.</description>
          <population>Intent to treat population included all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PFS 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.45" lower_limit="4.21" upper_limit="5.68"/>
                    <measurement group_id="O2" value="3.98" lower_limit="3.38" upper_limit="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PFS 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.01" lower_limit="2.86" upper_limit="4.47"/>
                    <measurement group_id="O2" value="2.60" lower_limit="2.33" upper_limit="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PFS 2: The stratification factors for Log-Rank test are the type of planned 2nd-line SoC treatment, the number of cycles of bevacizumab maintenance treatment prior to PD1 and the smoking status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0573</p_value>
            <method>Stratified Log-Rank test</method>
            <param_type>Stratified Hazard Ratio</param_type>
            <param_value>0.83</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PFS 3: The stratification factors for Log-Rank test are the type of planned 2nd-line SoC treatment, the number of cycles of bevacizumab maintenance treatment prior to PD1 and the smoking status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0045</p_value>
            <method>Stratified Log-Rank test</method>
            <param_type>Stratified Hazard Ratio</param_type>
            <param_value>0.63</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.49</ci_lower_limit>
            <ci_upper_limit>0.83</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Objective Response According to RECIST v1.1</title>
        <description>The objective response is defined as complete response (CR) or partial response (PR) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR.</description>
        <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
        <population>Intent to treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Standard of Care</title>
            <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Objective Response According to RECIST v1.1</title>
          <description>The objective response is defined as complete response (CR) or partial response (PR) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR was defined as greater than or equal to (≥) 30 percent (%) decrease in sum of longest diameter (LD) of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR.</description>
          <population>Intent to treat population included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" lower_limit="5.86" upper_limit="12.21"/>
                    <measurement group_id="O2" value="6.3" lower_limit="3.91" upper_limit="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The stratification factors for Cochran-Mantel-Haenszel test are the type of planned 2nd-line SoC treatment, the number of cycles of Bevacizumab maintenance treatment prior to PD1 and the smoking status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0810</p_value>
            <method>Stratified Cochran-Mantel-Haenszel test</method>
            <param_type>Estimated difference in response rate</param_type>
            <param_value>0.0237</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0156</ci_lower_limit>
            <ci_upper_limit>0.0630</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Disease Control According to RECIST v1.1</title>
        <description>The disease control rate is defined as CR or PR or stable disease (SD) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started for target lesions and the persistence of 1 or more non-target lesions.</description>
        <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
        <population>Intent to treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Standard of Care</title>
            <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Disease Control According to RECIST v1.1</title>
          <description>The disease control rate is defined as CR or PR or stable disease (SD) assessed according to the RECIST v.1.1 criteria with baseline tumour assessment as the reference. SD was defined as neither sufficient shrinkage to qualify for a PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started for target lesions and the persistence of 1 or more non-target lesions.</description>
          <population>Intent to treat population included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2" lower_limit="75.57" upper_limit="84.36"/>
                    <measurement group_id="O2" value="77.0" lower_limit="72.06" upper_limit="81.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The stratification factors for Cochran-Mantel-Haenszel test are the type of planned 2nd-line SoC treatment, the number of cycles of Bevacizumab maintenance treatment prior to PD1 and the smoking status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0218</p_value>
            <method>Stratified Cochran-Mantel-Haenszel test</method>
            <param_type>Estimated difference in Disease Control</param_type>
            <param_value>0.0326</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0288</ci_lower_limit>
            <ci_upper_limit>0.0940</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR) According to RECIST v1.1</title>
        <description>Duration of response is defined as the time that measurement criteria are met for objective response (CR/PR) (whichever status is recorded first) until the first date of progression or death is documented. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than &lt; 10 mm. PR was defined as greater than or equal to ≥30 % decrease in sum of longest diameter of target lesions in reference to baseline sum longest diameter.</description>
        <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
        <population>Intent to treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Standard of Care</title>
            <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR) According to RECIST v1.1</title>
          <description>Duration of response is defined as the time that measurement criteria are met for objective response (CR/PR) (whichever status is recorded first) until the first date of progression or death is documented. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than &lt; 10 mm. PR was defined as greater than or equal to ≥30 % decrease in sum of longest diameter of target lesions in reference to baseline sum longest diameter.</description>
          <population>Intent to treat population included all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.46" lower_limit="5.39" upper_limit="8.54"/>
                    <measurement group_id="O2" value="6.24" lower_limit="3.52" upper_limit="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The stratification factors for Log-Rank test are the type of planned 2nd-line SoC treatment, the number of cycles of Bevacizumab maintenance treatment prior to PD1 and the smoking status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0600</p_value>
            <method>Stratified Log-Rank test</method>
            <param_type>Stratified Hazard Ratio</param_type>
            <param_value>0.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.</description>
        <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
        <population>The safety population included all participants who had received at least one dose of any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Standard of Care</title>
            <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant.</description>
          <population>The safety population included all participants who had received at least one dose of any study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5"/>
                    <measurement group_id="O2" value="96.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP) According to RECIST v1.1</title>
        <description>The time to progression was defined as the time from baseline until disease progression as determined by the RECIST v1.1. TTP2 is defined as the interval between the day of randomization at PD1 and PD2. TTP3 is defined as the interval between the day of PD2 and PD3. PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.</description>
        <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
        <population>Intent to treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Standard of Care</title>
            <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP) According to RECIST v1.1</title>
          <description>The time to progression was defined as the time from baseline until disease progression as determined by the RECIST v1.1. TTP2 is defined as the interval between the day of randomization at PD1 and PD2. TTP3 is defined as the interval between the day of PD2 and PD3. PD was defined as ≥20% increase in sum LD in reference to the smallest on-study sum LD, or the appearance of new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.</description>
          <population>Intent to treat population included all randomized participants.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TTP2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.55" lower_limit="4.86" upper_limit="6.18"/>
                    <measurement group_id="O2" value="4.21" lower_limit="3.75" upper_limit="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TTP3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" lower_limit="3.25" upper_limit="4.63"/>
                    <measurement group_id="O2" value="2.73" lower_limit="2.37" upper_limit="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TTP2: The stratification factors for Log-Rank test are the type of planned 2nd-line SoC treatment, the number of cycles of Bevacizumab maintenance treatment prior to PD1 and the smoking status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0311</p_value>
            <method>Stratified Log-Rank test</method>
            <param_type>Stratified Hazard Ratio</param_type>
            <param_value>0.79</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.65</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>TTP3: The stratification factors for Log-Rank test are the type of planned 2nd-line SoC treatment, the number of cycles of Bevacizumab maintenance treatment prior to PD1 and the smoking status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0326</p_value>
            <method>Stratified Log-Rank test</method>
            <param_type>Stratified Hazard Ratio</param_type>
            <param_value>0.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Are Alive at Month 6, 12, and 18</title>
        <description>Percentage of participants who were alive at Month 6, 12 and 18 were reported.</description>
        <time_frame>Month 6, 12, 18</time_frame>
        <population>Intent to treat population included all randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Bevacizumab + Standard of Care</title>
            <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Are Alive at Month 6, 12, and 18</title>
          <description>Percentage of participants who were alive at Month 6, 12 and 18 were reported.</description>
          <population>Intent to treat population included all randomized participants.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="240"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="0.73" upper_limit="0.82"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.62" upper_limit="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.44" upper_limit="0.54"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0.39" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.31" upper_limit="0.41"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0.25" upper_limit="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to data cut-off date 24 June 2016 (approximately 5 years)</time_frame>
      <desc>The safety population included all participants who had received at least one dose of any study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Bevacizumab + Standard of Care</title>
          <description>Participants received bevacizumab on Day 1 of every 21-days cycle along with standard of care, until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>Participants received investigator's choice of standard of care (Erlotinib or Docetaxel or Pemetrexed) according to local practice until the occurrence of an unacceptable toxicity or withdrawal of consent (whichever occurs first).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="126" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Febrile Bone Marrow Aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pure White Cell Aplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Aplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Tracheo-oesophageal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia Strangulated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Mechanical Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Oesophageal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pneumatosis Intestinalis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Small Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Performance Status Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile Duct Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Liver Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal Abcess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary Aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Device related Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Diarrhoea Infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Febrile Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Genital Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Lung Abcess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Periorbital Abcess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Post Procedural Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Psoas Abcess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Respiratory tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abcess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Arterial Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Liver Function Test Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Lymphocyte Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Tetany</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Intervetebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Metastases to Adrenals</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Parapalegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Peripheral Motor Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Posterior Reversible Encephalopathy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Nephrotic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Prerenal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Renal Tubular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Bronchial Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Organizing Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pulmonary Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pulmonary Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Erythema Multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Skin Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Osteosynthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Peripheral Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="226" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="215" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation Increased</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="73" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dermatitis Acneiform</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="232"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="243"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="232"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>888-6821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

